Background: Kaposi's sarcoma-associated herpesvirus (KSHV) is associated with several malignant diseases, including Kaposi's sarcoma, primary effusion lymphoma (PEL) and multicentric Castleman's disease. The objectives of this study were to investigate the use of peptideconjugated phosphorodiamidate morpholino oligomers (PPMOs) against KSHV early lytic genes and to assess their efficacy in severe combined immunodeficiency disease (SCID) mice against PEL engraftment. PPMOs are short, single-stranded DNA analogues that contain a backbone of morpholine rings and phosphorodiamidate linkages and have high delivery efficiency into cells. Methods: PEL cells were treated with PPMOs against viral interferon regulatory factor 1 (vIRF-1) and expression of vIRF-1 was analysed. PPMOs against vIRF-1 and viral interleukin-6 (vIL-6) were evaluated against PEL cell engraftment in SCID mice. The PPMOs were incubated with BCBL-1 cells and then introduced into the peritoneal cavities of SCID mice, followed by 9 more doses of PPMOs administered at 2-day intervals. At weeks 3 and 9 after BCBL-1 delivery, peritoneal lavage was collected and the ratio of PEL cells among total cells was determined by flow cytometry analysis. Results: Treatment of PEL cells with PPMOs against vIRF-1 led to a reduction of vIRF-1 expression in a dosedependent manner. Reduction of vIRF-1 expression resulted in higher levels of cellular interferon regulatory factor 3 and of signal transducer and activator of transcription 1. SCID mice receiving a PPMO against vIL-6 had no engraftment of PEL cells and remained healthy throughout the 120-day study. Conclusions: This study showed that PPMOs can be effective antiviral agents against KSHV. Blocking the expression of early lytic genes might be beneficial for the control of KSHV-associated malignant diseases.
Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8, is associated with several malignant diseases including Kaposi's sarcoma (KS), primary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD) [1, 2] . Despite the use of HAART, which has reduced the incidence of KS, the disease remains the most common malignancy in patients with AIDS in developed countries [3] . Current anti-herpesvirus drugs, such as ganciclovir, cidofovir and foscarnet, target the DNA polymerase expressed during the late lytic phase of KSHV replication and have limited benefits against either KS or PEL [4, 5] . Specific anti-KSHV drugs are still much needed for the treatment of KSHV-associated malignancies. In this study, peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) were used to inhibit expression of KSHV early lytic genes and to suppress engraftment of PEL cells in mice with non-obese diabetic/severe combined immunodeficiency disease (NOD/SCID).
PPMOs are short, single-stranded DNA analogues that contain a backbone of morpholine rings and phosphorodiamidate linkages [6] . PPMOs bind to complementary target messenger RNA (mRNA) by WatsonCrick base pairing and block translation through steric blockade. This is a distinctly different process from the RNase H dependent mechanism induced by other antisense structural types, such as phosphorothioate DNA [6] . The sequence-specific antiviral efficacy of PPMOs 
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has been documented against a number of RNA viruses in animal models, including Ebola virus [7, 8] , Coxsackievirus B3 [9] , murine Coronavirus [10] , Dengue virus [11] and West Nile virus [12, 13] . KSHV is a large, double-stranded DNA virus encoding over 80 genes [14] . Like other herpesviruses, KSHV displays a tightly regulated programme of gene expression using two modes of infection: latent and lytic. The reactivation of KSHV lytic replication in PEL cells can be induced by chemicals, such as tetradecanoyl phorbol acetate (TPA) [15] . Lytic replication can be divided into immediate-early, early and late stages, based on the expression time of viral genes after activation of the lytic cycle. Two of the KSHV early lytic genes, encoding viral interferon regulatory factor 1 (vIRF-1) and viral interleukin-6 (vIL-6), are among those that have been implicated in the pathogenesis of KSHV-associated malignant diseases.
vIRF-1 is encoded by open reading frame (ORF)-K9 and has homology to members of the cellular interferon regulatory factor family. vIRF-1 interacts with IRF-1, IRF-3, p53 and CREB-binding protein/p300 proteins to inhibit type I/II human interferon (IFN) signalling and leads to transformation of NIH3T3 cells, as well as induction of tumours in nude mice [16] [17] [18] [19] . The IRF family members are transcription regulatory factors that bind to interferon-stimulated response elements to regulate interferon-responsive genes involved in pathogen response, cytokine signalling, cell growth regulation and haematopoietic development [20] . The vIRF-1 protein directly interacts with these DNAbinding proteins to interfere with their functions [21, 22] . vIRF-1 inhibits the ATM/p53 signal transduction pathway by down-regulating the p53 total protein level [23] . These findings suggest that vIRF-1 is an oncogenic protein and can potentially contribute to KSHV-driven malignancies.
ORF-K2 encodes vIL-6; vIL-6 is expressed in only a few cells of KS lesions, but is expressed in a greater number of cells in PEL and MCD lesions, indicating a role for vIL-6 in KSHV-associated lymphoproliferative disorders [24] [25] [26] [27] . vIL-6 is a homologue of human IL-6 (hIL-6), an important autocrine/paracrine growth factor, and is notably expressed at a high level in some lymphomas [1, 2] . vIL-6 can stimulate all of the known hIL-6-induced signalling pathways [28, 29] . Treatment of BCBL-1 cells with a PPMO against vIL-6 leads to inhibition of vIL-6 expression and, as a result, slower cell growth [30] . Thus, vIL-6 is a multifunctional cytokine that can potentially contribute to KSHV-associated lymphoproliferative disorders.
Considering the important roles of vIRF-1 and vIL-6, we selected these genes as targets for the development of anti-KSHV PPMOs. The PPMOs were tested in cell cultures of PEL cells and in NOD/SCID mice engrafted with BCBL-1 cells. BCBL-1 cells were derived from a primary effusion lymphoma patient and were successfully engrafted into SCID mice [31] . In this study, we found that two anti-vIRF-1 PPMOs effectively inhibited vIRF-1 expression in PEL cells, as shown by western blotting analysis. In NOD/SCID mice, administration of a PPMO against vIL-6 effectively blocked engraftment of BCBL-1 cells.
Methods

Cells and viruses
KSHV-infected BCBL-1 (NIH AIDS Research & Reference Reagent Program, Bethesda, MD, USA) and BCP-1 (CRL-2294; American Type Culture Collection, Manassas, VA, USA) cells were derived from body cavity based lymphomas [15, 32] . Both cell lines were maintained in RPMI 1640 medium supplemented with 10% foetal bovine serum. For induction of KSHV lytic replication, 12-O-tetradecanoyl phorbol 13-acetate (TPA; Sigma, St Louis, MO, USA) was added to the cell growth medium to a final concentration of 20 ng/ml.
PPMO design and synthesis
PPMOs against vIRF-1 were designed to be complementary to the 5′-terminal region of the vIRF-1 mRNA sequence. The sequences (5′ to 3′) of the anti-vIRF-1 PPMOs used in this study were KP1 (GCCTGGGTC-CATTGTCCCGC; italicized nucleotides correspond to the translation initiation codon AUG of vIRF-1 mRNA) and KP2 (TAGCCGCAGAATTGCCTGGGT). KP1 is complementary to nucleotides 152-172 and KP2 complements nucleotides 1-22 of the vIRF-1 mRNA sequence (GenBank accession number AF145701). PPMOs were produced at AVI BioPharma Inc. (Corvallis, OR, USA) and conjugated to arginine-rich P007 peptide, as previously described [30] . A scramble PPMO (hereafter named CP1), having little agreement with KSHV or human mRNA sequences, was used as a negative control. ILP1, a PPMO against vIL-6, was described previously [30] .
PPMO treatment of KSHV-infected PEL cells
Treatment of KSHV-infected BCBL-1 and BCP-1 cells was conducted as reported previously [30, 33] . Briefly, the cells were pelleted and resuspended in RPMI 1640 medium and plated in a 12-well cell culture plate. PPMO was immediately added, mixed and incubated for 4 h at 37°C. Growth medium was then added to a final volume of 1.5 ml per well. For those cells to be induced with TPA, the medium was supplemented with TPA at 20 ng/ml. The cells were incubated for 48 h at 37°C and both cells and culture supernatant were then harvested for further analysis.
Western blotting analysis
Expression of KSHV proteins in KSHV-infected cells was detected by western blotting analysis, as described previously [33] . Rabbit anti-vIRF-1 antibody (a gift from Emory University, Atlanta, GA, USA), goat antirabbit immunoglobulin G conjugated with horseradish peroxidase (Sigma) and chemiluminescence substrate were used in this assay. Chemiluminescence signals were collected by ChemiDoc XRS digital imaging system (Bio-Rad Laboratories, Hercules, CA, USA). For normalization, β-tubulin was also detected on the same blot membrane after being stripped. Similarly, western blotting analysis was conducted with rabbit anti-IRF3 and rabbit anti-STAT1 (signal transducer and activator of transcription) antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Digital image analyses were conducted using Quantity One software (version 4.6; Bio-Rad).
Cell viability assay
The viability of BCBL-1 cells after PPMO or mock treatment was determined with CellTiter-Glo ® Luminescent Cell Viability Assay (Promega, Madison, WI, USA) as described previously [30] . Briefly, BCBL-1 cells were treated with KP1 and CP1 as described above. TPA was not used in this assay. Normal BCBL-1 cells were included for comparison. At 48 h after the PPMO treatment, CellTiter-Glo reagent was added to the cells according to the manufacturer's instructions and the luminescence signal was then detected with a VIC-TOR3 TM Multilabel Counter (Perkin-Elmer Life and Analytical Sciences, Wellesley, MA, USA).
DNA isolation and real-time PCR
Genomic DNA from cell culture supernatant was isolated using DNAzol (Invitrogen, Carlsbad, CA, USA). Real-time PCR was conducted with a Chromo 4 Detector system and iQ SYBR Green Supermix (Bio-Rad), as described previously [30] . Primers from ORF73 were used to detect KSHV DNA. The plasmid pCDNA3-ORF73 was used to generate a standard curve for quantification of KSHV DNA copies in culture supernatant.
Engraftment of BCBL-1 cells to SCID mice and PPMO treatment
NOD/SCID female mice (6 weeks old) were purchased from Animal Production Program, National Cancer Institute (Frederick, MD, USA). The mice were housed in micro-isolator cages. All of the cages, food, water and bedding were autoclaved prior to use. The animal experiment protocol was approved by the Institutional Animal Care and Use Committee at the University of Maryland (College Park, MD, USA). Mice were monitored for clinical signs and ascites development and euthanized if a humane end point was reached according to our protocol.
BCBL-1 cells were delivered to the NOD/SCID mice via an intraperitoneal (ip) route at a dose of 1×10 7 cells per mouse, as described previously [31] . Peritoneal lavage of the mice was collected using 5 ml serum-free RPMI at 3-5 weeks post-inoculation. The BCBL-1 cells from in vivo propagation in SCID mice were used for the PPMO study in mice.
For PPMO study, five mice were used in each group. Mice in groups 1 to 4 received 1 million BCBL-1 cells via ip injection. Group 1 did not receive PPMO treatment. Groups 2 to 4 received treatment with KP1+KP2, ILP1 and CP1, respectively. Group 5 was used as a control that received no BCBL-1 cells or PPMO. In the groups that were given a PPMO treatment, the BCBL-1 cells were treated with PPMOs at a final concentration of 16 µM for 2 h before being ip injected into SCID mice; phosphate-buffered saline was used as mock treatment in a negative control group. The mice were injected with PPMOs nine more times at 2-day intervals at a dose of 5 mg/kg (that is, about 100 µg in a 500 µl volume per mouse). The mice were observed daily and subjected to peritoneal lavage collection at 3 and 9 weeks after BCBL-1 injection. To assess tumour cell burden, a fraction of lavage sample cells were stained with phycoerythrin-conjugated monoclonal antibody against human CD45, a common leukocyte antigen, and fluorescein isothiocyanate conjugated antibody against murine CD45.2 (BD Biosciences/Pharmingen, San Diego, CA, USA), as described previously [31] . Flow cytometry analysis was conducted to determine the ratio of BCBL-1 in the total number of cells from lavage samples.
Statistical analysis
A single-factor ANOVA statistical analysis was used to analyse statistical differences between the treatment groups. A two-tailed P-value <0.05 was considered to be a significant difference.
Results
PPMO against ORF-K9 inhibits vIRF-1 expression in a transient transfection
The 5′-untranslated region (5′-UTR) of vIRF-1 mRNA is 159 nucleotides long [34] ; there is no internal ribosome entry site in the 5′-UTR. The region around the translation initiation codon of the vIRF-1 transcript was initially selected as the target for PPMO design. KP1, complementary to this region, was first designed and tested for its effect on the inhibition of vIRF-1 expression. Later, another vIRF-1 PPMO, KP2, was designed to confirm the sequence-specific inhibition of KP1. KP2 is complementary to the 5′ terminus of vIRF-1 mRNA, which is also an important region for ribosome binding and scanning in translation of the mRNA. A scramble PPMO (CP1), containing a random sequence, was included as a negative control. All the PPMOs were checked in a Blast search of the National Centre for Biotechnology Information to make sure there were no potential targets to cellular genes.
To test the effect of KP1 on target gene expression, we cloned ORF-K9 and the 5′-UTR of vIRF-1 mRNA upstream of the gene encoding green fluorescent protein (GFP) in a pEGFP-N1 vector, in order to express it as vIRF-1-GFP fusion protein. The resulting plasmid pEGFP-vIRF-1 was transiently transfected into HEK293 cells. Treatment of the cells with 16 µM KP1 was conducted 2 h after transfection and CP1 was included as a control. At 24 h post-transfection, the cells were observed under fluorescence microscopy. In comparison with CP1-treated cells, the KP1-treated cells had far fewer cells with green fluorescence (Figure 1A ), indicating that KP1 suppressed translation of the target vIRF-1-GFP transcript. The CP1-treated cells had GFP-positive cells at a similar percentage to mock treated cells. The result indicates that KP1-mediated inhibition of vIRF-1-GFP fusion protein expression is sequence-specific. We then tested the PPMOs against vIRF-1 in KSHV-infected PEL cells.
Suppression of vIRF-1 expression in KSHV-infected PEL cells
An immunofluorescence assay was initially conducted with rabbit anti-vIRF-1 antibody to detect vIRF-1 in BCBL-1 cells. After TPA induction, approximately 20% of the cells expressed vIRF-1, as expected. Fewer than 5% of the cells that were treated with 16 µM KP1 were vIRF-1-positive. To assess vIRF-1 levels, total proteins were separated by SDS-PAGE and detected by western blotting analysis with rabbit anti-vIRF-1 antibody. The results showed that KP1 treatment led to a reduction of vIRF-1 levels in BCBL-1 cells ( Figure 1B ). Densitometry analysis of the digital blot image showed that treatment of BCBL-1 cells with KP1 at 16 µM reduced vIRF-1 levels by 80%, in comparison with mock-treated BCBL-1 cells after TPA induction ( Figure 1B) . Treatment of BCBL-1 cells with CP1 had a negligible effect on vIRF-1 protein levels. These results suggest that KP1 inhibited vIRF-1 expression in BCBL-1 cells.
PPMO KP1 was also tested in BCP-1, another cell line of PEL, to ensure that the inhibition is not cell-line specific. The cells were treated with 16 µM KP1 or CP1 and harvested 48 h post-treatment. Western blotting analysis showed that the KP1 treatment reduced vIRF-1 levels in BCP-1 cells by 90% ( Figure 1C ), whereas CP1 did not have an effect in comparison with the mocktreated control.
PPMO KP2 complements a site that is 152 nucleotides upstream of the KP1 complementary site in vIRF-1 mRNA. Treatment of BCBL-1 cells with KP2 also reduced the vIRF-1 levels by 80% in comparison with the mock-treated control ( Figure 1D ). The KP2 inhibitory effect was similar to the effect of KP1 and confirmed that the PPMO-mediated inhibition is sequence-specific. This indicates that the 5′-UTR of vIRF-1 mRNA is a productive region for PPMO targeting.
We further tested the dose-response effect of PPMO treatment in inhibition of vIRF-1 expression in BCBL-1 cells. KP1 was used as both KP1 and KP2 had similar effects. As the concentration of KP1 was increased incrementally from 0.5 to 16 µM, the vIRF-1 level in TPA-induced BCBL-1 cells decreased in a dose-dependent manner ( Figure 1E ). By contrast, treatment with CP1 had little effect on the expression of vIRF-1 in the TPA-induced BCBL-1 cells.
Cell culture supernatant was also harvested for DNA isolation and real-time PCR to measure KSHV DNA levels. TPA induction led to an elevation of the KSHV viral DNA levels by an average of 39-fold. The KSHV DNA in the supernatant from KP1-treated cells was significantly reduced by 42% in comparison with the CP1-treated control (Additional file 1). The result suggests that KP1 treatment resulted in a reduction of KSHV replication in TPA-induced BCBL-1 cells.
We conducted a cell viability assay to make sure that the PPMO did not have toxicity to the PEL cells at the concentration used. The cell viability assay did not detect any significant changes in cell numbers of BCBL-1 cells after KP1 or CP1 treatment. The relative percentage of cell viability of BCBL-1 cells treated with KP1 was 97% in comparison with non-treated cells (Additional file 2). The result indicates that the PPMOs were non-toxic to the PEL cells at the concentration used.
Elevation of IRF-3 and STAT1 in BCBL-1 cells by KP1 treatment
As vIRF-1 interacts with cellular IRF-3, we speculated that suppression of vIRF-1 would have an effect on IRF-3 expression. Because KP1 and KP2 have a similar effect on vIRF-1 expression, we used only KP1 for this experiment. We tested the IRF-3 protein levels in BCBL-1 cells treated with 16 µM KP1 or CP1. Mock-treated cells were also included for comparison. It was interesting to note that TPA induction led to a reduction of the IRF-3 level (Figure 2A) . The cells treated with KP1 had a sixfold higher IRF-3 level than those treated with CP1. This result suggests that the KP1 treatment suppressed vIRF-1 expression and relieved the inhibition of IRF-3 expression.
In the interferon signalling pathway, STAT1, an important transcription factor, is needed for activating the expression of IFN-responsive genes. We speculated that KP1-mediated suppression of vIRF-1 would have an effect on STAT1. In BCBL-1 cells treated with KP1, the STAT1 level was higher than that in cells treated 
PPMO treatment reduces BCBL-1 engraftment in SCID mice
The SCID mouse model of PEL engraftment was used to assess the efficacy of the PPMOs in vivo. BCBL-1 cells propagated in the ip cavity of SCID mice were used in this experiment. When the BCBL-1 cells propagated in vivo were inoculated into naive SCID mice, the development of ascites and tumours was much quicker than for mice inoculated with BCBL-1 cells cultured in vitro.
As both KP1 and KP2 were effective in the inhibition of vIRF-1 expression in cell culture, and as both target vIRF-1 mRNA, we combined them in one group in the mouse experiment for a more effective inhibition. ILP1, a PPMO against vIL-6 of KSHV, was also tested as it was shown to be effective in inhibiting vIL-6 expression and resulted in reduction of cell growth in culture [30] . A scramble PPMO (CP1) was included as a negative control. Five mice were used in each group. BCBL-1 cells were incubated with PPMOs for 2 h before being injected into the peritoneal cavities of the mice. The PPMOs were administered nine more times in 2-day intervals. At week 3 after injection of BCBL-1 cells, peritoneal lavage was collected and cells were stained to determine the ratio of PEL cells in the lavage. The mice treated with ILP1 had a significant average lower ratio of PEL cells, <2% of total cells ( Figure 3A) , which is at the background level and is negligible. Two mice of the KP1+KP2 group had a low ratio of PEL cells, 3.94 and 7.01%, respectively (Table 1) , although the average ratio of PEL cells in this group was similar to those treated with scramble PPMO or untreated control. All five mice in the ILP1 group had a very low ratio (<10%) of PEL cells. All mice treated with CP1 and the mock-treated group had a relatively high ratio (>20%) of BCBL-1 cells, indicating efficient engraftment of the PEL cells.
At week 9 after injection of BCBL-1 cells, peritoneal lavage was collected again. All mice in the ILP1 group had a negligible ratio (<3%) of PEL cells ( Figure 3B and Table 1 ) and all were healthy. The average ratios of BCBL-1 cells in the lavage of KP1+KP2, CP1 and negative control groups were 45, 60 and 83%, respectively. One mouse in the KP1+KP2 group had a negligible ratio (1.98%) of BCBL-1 cells in its peritoneal lavage (Table 1 ). Those mice that had a high ratio (>20%) of BCBL-1 cells at week 3 still had a similar or higher ratio of the cells at week 9.
All mice in the CP1 control group receiving BCBL-1 cells were euthanized before or on day 77 as a humane end point was reached ( Table 1 ). The mice in the ILP1 group were still healthy when the study ended on day 120 after BCBL-1 cell injection. No ascites development was noticed in the mice of the ILP1 group. This result suggests that ILP1 suppressed BCBL-1 engraftment in the mice. The survival time of all mice of the ILP1 group was much longer than for the others ( Figure  4 and Table 1 ). These mice remained healthy through to the end of the study at day 120 after delivery of BCBL-1 cells, as did one mouse of the KP1+KP2 group. All other mice died or were euthanized before day 77. One mouse in the KP1+KP2 group that had a negligible ratio (7%) of BCBL-1 cells at week 3 died accidently during handling on day 38. These data indicate that ILP1 inhibited BCBL-1 engraftment in SCID mice.
Discussion
In this study, we explored the use of PPMOs against the early lytic genes vIRF-1 and vIL-6 and demonstrated that the anti-vIRF-1 PPMOs inhibited vIRF-1 expression in two KSHV-infected PEL cell lines, BCBL-1 and BCP-1. The PPMO ILP1 against vIL-6 protected SCID mice from PEL engraftment. We designed and tested two PPMOs complementary to the 5′-UTR and the translation initiation region of vIRF-1 mRNA. Both PPMOs worked efficiently in inhibiting vIRF-1 expression in BCBL-1 cells, indicating that the 5′-UTR is crucial for vIRF-1 translation. Our finding is consistent with previous publications on the inhibition of vIRF-1 by antisense RNA or by the ribozyme [35, 36] . KSHV replication was also reduced in KP1-treated PEL cells. We speculated that the reduction of KSHV lytic replication might be a result of alleviation of vIRF-1 inhibition of the cellular IFN signalling pathway. Our data on elevation of IRF-3 and STAT1 in KP1-treated cells also support this speculation. BCBL-1 cells, after vIRF-1 inhibition, had higher levels of IRF-3 and STAT1, both of which have an important role in IFN signalling and the antiviral response. The elevation of these cellular genes in the IFN signalling pathway is an encouraging result for further exploration of the PPMOs as a potential intervention of KSHV-associated malignant diseases.
We conducted a cell viability assay and did not detect any significant change in cell numbers 2 days after KP1 treatment of BCBL-1 cells. As vIRF-1 is expressed in a low ratio of normal PEL cells, the suppression of vIRF-1 might not result in an immediate effect on cell growth. Severe combined immunodeficiency disease (SCID) mice with BCBL-1 engraftment were subdivided into four groups that received either phosphate-buffered saline (mock treatment) or one of three phosphorodiamidate morpholino oligomer (PPMO) treatments: KP1+KP2, ILP1 (designed against viral interleukin-6) or CP1 (a negative control). Severe combined immunodeficiency disease (SCID) mice with BCBL-1 engraftment were subdivided into four groups that received either phosphatebuffered saline (mock treatment) or one of three phosphorodiamidate morpholino oligomer (PPMO) treatments: KP1+KP2, ILP1 or CP1 (a negative control). One mouse in the mock treatment group, one mouse in the CP1 group and two mice in the KP1+KP2 group died before or during week 8. All five mice in the ILP1 group and one mouse in the KP1+KP2 group were still healthy by week 17. All other mice were euthanized in week 11 owing to poor health conditions. Observation ended at week 17.
Our earlier study showed that PPMOs can specifically suppress protein expression of KSHV replication and transcription activator (RTA), latency-associated nuclear antigen (LANA) and vIL-6 [30, 33] . Application of an RTA-specific PPMO to BCBL-1 cells resulted in reduction of KSHV viral DNA levels in intracellular and culture supernatant samples. Blockage of vIL-6 expression resulted in slower growth of BCBL-1 cells. This current study showed that vIRF-1 can be another productive target for inhibition of KSHV infection. These results indicate that blocking expression of latent and early lytic genes is an effective strategy to inhibit KSHV infection and might lead to beneficial effects for the control of KSHV-associated malignant diseases.
The SCID mouse model of PEL represents an effective in vivo approach to assess the efficacy of the PPMOs in inhibiting the PEL engraftment. The PPMO ILP1 against vIL-6 blocked PEL development in SCID mice, which is consistent with its effective inhibition of vIL-6 expression and BCBL-1 growth [30] . The two PPMOs against vIRF-1 were less effective in SCID mice; however, two of the five mice had negligible engraftment of BCBL-1 cells, indicating that the dose of anti-vIRF-1 PPMOs was not sufficient to have an extending inhibitory effect on BCBL-1 cells in SCID mice. Another possible reason for this observation is that vIRF-1 expression might be dispensable in the PEL engraftment in SCID mice.
Current anti-herpesvirus drugs target the late lytic phase of herpesvirus replication and it has been reported that cidofovir and foscarnet are the most efficient commercially available compounds against KSHV [37] [38] [39] . Cidofovir and foscarnet have no effect on the expression of latent or early lytic genes [40] , as these drugs are inhibitors of the viral DNA polymerase and transcription of early lytic genes occurs before DNA replication in KSHV. Early lytic genes such as vIL-6 and vIRF-1 have important roles in KSHV replication and pathogenesis. Our results indicate that vIRF-1 and vIL-6 could be effective targets for antiviral therapy. Additionally, inhibition of the early lytic genes might have positive implications for managing KSHV-induced lymphoma development. Further studies to investigate the capacity of PPMOs to suppress KSHV tumourigenesis are needed.
